scholarly journals The Prognostic Determinant of Interleukin-10 in Patients with Acute Ischemic Stroke: An Analysis from the Perspective of Disease Management

2021 ◽  
Vol 2021 ◽  
pp. 1-9
Author(s):  
Wen Sun ◽  
Shuhui Wang ◽  
Shanji Nan
Keyword(s):  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Inflammatory Cytokine ◽  
Serum Levels ◽  
Interleukin 10 ◽  
Clinical Severity ◽  
Anti Inflammatory ◽  
Anti Inflammatory Cytokine

Background. In patients with ischemic stroke, the role of anti-inflammatory cytokine Interleukin-10 (IL-10) in predicting risk and outcomes is not very clear. This study is aimed at prospectively assessing the prognostic determinant value of IL-10 in patients with acute ischemic stroke in a cohort of Chinese people. Methods. In a prospective cohort study, consecutive first-ever patients with acute ischemic stroke admitted to our hospital were included from October 2019 to October 2020. The serum level of IL-10 was measured at baseline. A structured follow-up telephone interview was performed on day 90 after admission. Logistic regression analyses were used to assess the prognostic value of IL-10 to predict the poor functional outcome (defined as a modified Rankin Scale score of 3 to 6) and mortality. Results. The median age of the 236 enrolled patients was 65 years (interquartile range (IQR), 56-76), and 57.6% were male. There was a negative correlation between the National Institutes of Health Stroke Scale (NIHSS) score and IL-10 serum levels ( r   Spearman = − 0.221 , P = 0.001 ). Patients with elevated IL-10 levels (> the highest quartile = 5.24   pg / mL ; n = 79 ) were at significantly lower risk of poor functional outcomes (odds ratio (OR), 0.35; 95% confidence interval (CI), 0.19 to 0.63; P < 0.001 ) and mortality ( OR = 0.24 ; 95% CI = 0.11 –0.52; P < 0.001 ) compared with patients with IL-10 levels in the lowest three quartiles. Conclusions. Reduced serum levels of IL-10 were independently associated with both the clinical severity at admission and a poor functional prognosis in ischemic stroke patients, suggesting that the anti-inflammatory cytokine IL-10 was an important prognostic determinant.

Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure

2003 ◽  
Vol 105 (1) ◽  
pp. 45-50 ◽  
Author(s):  
Christian STUMPF ◽  
Christoph LEHNER ◽  
Atilla YILMAZ ◽  
Werner G. DANIEL ◽  
Christoph D. GARLICHS
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Inflammatory Cytokine ◽  
Serum Levels ◽  
Interleukin 10 ◽  
Anti Inflammatory ◽  
Anti Inflammatory Cytokine

scholarly journals The Role of the Anti-Inflammatory Cytokine Interleukin-10 in Tissue Fibrosis

2020 ◽  
Vol 9 (4) ◽  
pp. 184-198 ◽  
Author(s):  
Emily H. Steen ◽  
Xinyi Wang ◽  
Swathi Balaji ◽  
Manish J. Butte ◽  
Paul L. Bollyky ◽  
...  
Keyword(s):  
Inflammatory Cytokine ◽  
Interleukin 10 ◽  
Tissue Fibrosis ◽  
Anti Inflammatory ◽  
Anti Inflammatory Cytokine

Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina

2002 ◽  
Vol 144 (5) ◽  
pp. 811-817 ◽  
Author(s):  
Ignasi Anguera ◽  
Faustino Miranda-Guardiola ◽  
Xavier Bosch ◽  
Xavier Filella ◽  
Marta Sitges ◽  
...  
Keyword(s):  
Unstable Angina ◽  
Inflammatory Cytokine ◽  
Serum Levels ◽  
Interleukin 10 ◽  
Anti Inflammatory ◽  
Coronary Events ◽  
Anti Inflammatory Cytokine

Abstract 43: Renal Hemodynamic and Excretory Responses to Systemic Administration of Interleukin-10 in Anesthetized Mice

Hypertension ◽  
2013 ◽  
Vol 62 (suppl_1) ◽  
Author(s):  
Alexander Castillo ◽  
Dewan S Majid
Keyword(s):  
Receptor Antagonist ◽  
Inflammatory Cytokine ◽  
Interleukin 10 ◽  
Renal Tissue ◽  
Excretory Function ◽  
Anti Inflammatory ◽  
Renal Vascular ◽  
Renal Responses ◽  
Anti Inflammatory Cytokine

Recent studies have demonstrated that the anti-inflammatory cytokine, interleukin-10 (IL-10) is normally present in plasma and its protein is constitutively expressed in the renal tissue. However, the possible role of IL-10 in the regulation of renal hemodynamics and excretory function is not yet clearly defined. In the present study, we have examined the systemic and renal responses to intravenous administration of incremental doses of recombinant mouse IL-10 (0.015, 0.075 and 0.15 ng/min/g ; 45 min in each dose) in anesthetized mice (n=5). To determine the specificity of IL-10 actions, the responses to the middle dose were also assessed in the presence of its receptor antagonist, (mouse IL-10 Rα antibody; 1.5 ng/min/g; R&D system) in a separate group of mice (n=6). Standard clearance techniques were used to assess renal responses to infusions of IL-10 and its receptor antagonist. Renal blood flow (RBF) was determined by PAH clearances and glomerular filtration rate (GFR) was determined by inulin clearance. Infusion of IL-10 doses resulted in significant decreases in systemic mean arterial pressure (MAP; 98±1.9 to 89±3.9, 88±2.6 and 84±3.3 mmHg) and renal vascular resistance (RVR, 13.5±1.1 to 9.1±0.6, 7.1±0.5 and 7.1±0.5 mmHg/mL/min/g), increases in RBF (7.4±0.5 to 9.7±0.6, 10.6±0.5 and 9.8±0.6 mL/min/g) and GFR (1.06±0.05 to 1.45±0.13, 1.51±0.13 and 1.53±0.28 mL/min/g) without significant changes in urine flow (6.6±0.5 to 5.3±0.5, 5.5±1.1 and 5.3±1.1 μL/min/g ) or sodium excretion (0.58±0.08 to 0.52±0.18, 0.57±0.19 and 0.69±0.26 μmol/min/g). Administration of IL-10 receptor antagonist alone did not cause significant changes in MAP (90±3.7 to 89±5.3 mmHg), RVR (11.5±1.9 to 11.6±3.0 mmHg/mL/min/g), RBF (8.8±1.3 to 10.4±2.5 mL/min/g), GFR (1.06±0.08 to 1.20±0.19 mL/min/g) or other renal parameters. Infusion of the middle dose of IL-10 in the receptor antagonist pretreated mice failed to cause significant changes in RBF or GFR or other parameters confirming the specificity of its receptor activity in the mediation of observed renal responses to IL-10 infusion. These data suggest that the anti-inflammatory cytokine, IL-10 exerts vasodilator and hyper-filtration effects in the kidney but minimally influences the renal excretory function.

scholarly journals Therapeutically Targeting Neuroinflammation and Microglia after Acute Ischemic Stroke

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Youngjeon Lee ◽  
Sang-Rae Lee ◽  
Sung S. Choi ◽  
Hyeon-Gu Yeo ◽  
Kyu-Tae Chang ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Inflammatory Responses ◽  
Secondary Injury ◽  
Initial Event ◽  
Stroke Models ◽  
Anti Inflammatory ◽  
Preclinical And Clinical Studies ◽  
Multiple Receptor

Inflammation has a pivotal role in the pathogenesis of ischemic stroke, and recent studies posit that inflammation acts as a double-edged sword, not only detrimentally augmenting secondary injury, but also potentially promoting recovery. An initial event of inflammation in ischemic stroke is the activation of microglia, leading to production of both pro- and anti-inflammatory mediators acting through multiple receptor signaling pathways. In this review, we discuss the role of microglial mediators in acute ischemic stroke and elaborate on preclinical and clinical studies focused on microglia in stroke models. Understanding how microglia can lead to both pro- and anti-inflammatory responses may be essential to implement therapeutic strategies using immunomodulatory interventions in ischemic stroke.

Sign in / Sign up

Export Citation Format

Share Document